The Effect of Nafamostat Mesilate in Prolonging Filter Patency With Patients on Continuous Renal Replacement Therapy
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
Continuous renal replacement therapy (CRRT) has been considered as an effective modality for
renal replacement therapy in hemodynamically unstable patients within intensive care unit
(ICU) except for the necessity of anticoagulation. The severity and peculiarities of ICU
patients often make it equivocal to use anticoagulation. This is a prospective randomized
controlled study to show the difference in filter life span and adverse event between HF1000
(nafamostat mesilate) group and M100 (heparin-free) group.